1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. BB Biotech AG
  6. News
  7. Summary
    BION   CH0038389992

BB BIOTECH AG

(BION)
  Report
Delayed Swiss Exchange  -  11:31 2022-08-12 am EDT
62.30 CHF   -0.95%
07/22BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
CI
07/22Swiss Investor BB Biotech Posts H1 Loss Amid Difficult Macroeconomic Environment
MT
07/22BB Biotech AG publishes its interim report
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2022

04/22/2022 | 03:18am EDT

BB Biotech AG reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was CHF 0.723 million compared to CHF 235.77 million a year ago. Net loss was CHF 299.86 million compared to net income of CHF 220.95 million a year ago. Basic loss per share from continuing operations was CHF 5.43 compared to basic earnings per share from continuing operations of CHF 3.99 a year ago. Diluted loss per share from continuing operations was CHF 5.43 compared to diluted earnings per share from continuing operations of CHF 3.99 a year ago.


© S&P Capital IQ 2022
All news about BB BIOTECH AG
07/22BB Biotech AG Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
07/22Swiss Investor BB Biotech Posts H1 Loss Amid Difficult Macroeconomic Environment
MT
07/22BB Biotech AG publishes its interim report
EQ
07/22BB BIOTECH AG : First signs of increased M&A activity due to attractive valuations
EQ
07/22BB BIOTECH : Q2 Interim Report
PU
07/22BB BIOTECH : Q2 Financial_Report
PU
05/24BB BIOTECH AG : Disruptive technologies are changing an entire industry
EQ
04/22BB Biotech AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/22BB Biotech Swings To Q1 Loss As Total Returns Plummet
MT
04/22BB Biotech AG publishes its interim report
EQ
More news
Analyst Recommendations on BB BIOTECH AG
More recommendations
Financials
Sales 2022 -298 M -316 M -316 M
Net income 2022 259 M 275 M 275 M
Net Debt 2022 283 M 300 M 300 M
P/E ratio 2022 -9,60x
Yield 2022 6,18%
Capitalization 3 426 M 3 632 M 3 632 M
EV / Sales 2022 -12,4x
EV / Sales 2023 7,41x
Nbr of Employees 10
Free-Float 97,7%
Chart BB BIOTECH AG
Duration : Period :
BB Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Last Close Price 62,30 CHF
Average target price 78,60 CHF
Spread / Average Target 26,2%
EPS Revisions
Managers and Directors
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BB BIOTECH AG-19.25%3 632
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068